Course of the modified Rodnan skin thickness score in systemic sclerosis clinical trials: Analysis of three large multicenter, double‐blind, randomized controlled trials
Open Access
- 30 July 2009
- journal article
- research article
- Published by Wiley in Arthritis & Rheumatism
- Vol. 60 (8) , 2490-2498
- https://doi.org/10.1002/art.24681
Abstract
Objective To assess the course of the modified Rodnan skin thickness score (MRSS) in 3 large, multicenter, double‐blind, randomized controlled trials (RCTs) of patients with diffuse cutaneous systemic sclerosis (dcSSc) with different baseline disease durations, as defined from the date of onset of the first dcSSc symptom (excluding Raynaud's phenomenon) or from the date of onset of the first dcSSc‐related symptom (including Raynaud's phenomenon). Methods Data from 3 RCTs examining high‐dose versus low‐dose D‐penicillamine (D‐Pen Trial), recombinant human relaxin versus placebo (Relaxin Trial), and oral bovine type I collagen versus placebo (Collagen Trial) treatment in patients with dcSSc were pooled and analyzed. Patients were divided into 5 groups according to their disease duration at baseline. The linear mixed model for correlated data was used to model the 2 predictors of MRSS: time in study (expressed in months after baseline) and baseline disease duration (expressed in months, calculated from the date of onset of the first symptom characteristic of dcSSc with and without Raynaud's phenomenon). Results At study entry, the mean MRSS value was 21.0 in the D‐Pen Trial cohort, 27.3 in the Relaxin Trial cohort, and 26.1 in the Collagen Trial cohort. Time in study was a significant predictor of improvement in MRSS regardless of the disease duration at baseline (P < 0.0001). Patients with a disease duration of ≥24 months showed a greater rate of decline as compared with patients with a disease duration of P < 0.05). Similar results were obtained when disease duration was reclassified by including the time of the first Raynaud's phenomenon symptom in the definition. Conclusion Our study confirms recent findings that in patients entered into these 3 RCTs, skin thickening did not follow the same trend in natural history as that seen in the dcSSc populations entered into early, open longitudinal studies previously reported. These findings have important implications for study design, in which “prevention of worsening” is the main objective.Keywords
This publication has 22 references indexed in Scilit:
- Relationship between change in skin score and disease outcome in diffuse cutaneous systemic sclerosis: Application of a latent linear trajectory modelArthritis & Rheumatism, 2007
- Outcome measures in systemic sclerosis: An update on instruments and current researchCurrent Rheumatology Reports, 2007
- Reliability, validity, and minimally important differences of the SF-6D in systemic sclerosisQuality of Life Research, 2007
- Recombinant human anti–transforming growth factor β1 antibody therapy in systemic sclerosis: A multicenter, randomized, placebo‐controlled phase I/II trial of CAT‐192Arthritis & Rheumatism, 2007
- Minimally important difference in diffuse systemic sclerosis: results from the d-penicillamine studyAnnals of the Rheumatic Diseases, 2006
- Responsiveness of the SF-36 and the Health Assessment Questionnaire Disability Index in a systemic sclerosis clinical trial.2005
- High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis: Analysis of a two-year, double-blind, randomized, controlled clinical trialArthritis & Rheumatism, 1999
- Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis.1995
- Skin thickness score in systemic sclerosis: an assessment of interobserver variability in 3 independent studies.1993
- The course of skin involvement in systemic sclerosis over three years in a trial of chlorambucil versus placeboArthritis & Rheumatism, 1993